Ashley Cordova sold $38k of NVCR
Chief Executive Officer at NovoCure Ltd. 2,053 shares at an average of $18.54, traded Mar 3, 2025, filed Mar 4, 2025.
Score components
- +25RoleCEO
- +6Trade size$38k at market
- 0Share of holdings soldSold 1.0% of holdings
- 0ClusterNo other insider selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -6.7%, 3m -6.3%, 6m -33.0%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001562180-25-001975, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Mar 3, 2025 | SOpen-market sale Ordinary Shares | -2,053 | $18.54 | $38k | 204,005 | Mar 4, 2025 |
Related signals
Other insiders at NovoCure Ltd and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 60Notable | NovoCure Ltd | Frank X Leonard Chief Executive Officer | $615k 34,273 shares | -7% | |
| 41Moderate | NovoCure Ltd | Jeryl L Hilleman director | $46k 2,945 shares | -18% | |
| 41Moderate | NovoCure Ltd | David Hung director | $46k 2,945 shares | -13% | |
| 36Weak | NovoCure Ltd | Gabriel Leung director | $46k 2,945 shares | -3% | |
| 36Weak | NovoCure Ltd | W Anthony Vernon director | $46k 2,945 shares | -1% | |
| 41Moderate | NovoCure Ltd | Timothy J Scannell director | $46k 2,945 shares | -17% | |
| 41Moderate | NovoCure Ltd | Allyson J Ocean director | $46k 2,945 shares | -21% | |
| 41Moderate | NovoCure Ltd | Kristin Stafford director | $46k 2,945 shares | -21% | |
| 46Moderate | NovoCure Ltd | Christoph Brackmann Chief Financial Officer | $85k 6,412 shares | -3% | |
| 64Notable | NovoCure Ltd | William F Doyle Executive Chairman | $933k 71,887 shares | -18% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.